Physician profile
Mostafa Salimi
NPI 1013095009
$358.04
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $67.08 · 2021: $27.76 · 2022: $31.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $102.87 | 2019-2022 | |
| Fujifilm Healthcare Americas Corporation | $50.00 | 2019 | |
| Amgen INC. | $47.46 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $42.68 | 2019-2020 | |
| Lundbeck LLC | $27.58 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.69 | 2019 | |
| Irhythm Technologies, INC. | $19.67 | 2022 | |
| Daiichi Sankyo INC. | $14.86 | 2019 | |
| Gilead Sciences, INC. | $14.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mostafa Salimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.